Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Clinical trial NCT02861573 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02861573
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-17
- Primary completion
- 2027-10-22
- Enrollment
- 1200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.